MedTrace Logo

A Study Investigating the Effects of Neprinol Study Product on Vascular Function

NCT02862223 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2017-01-09

No results posted yet for this study

Summary

This open-label study investigated the effectiveness of Neprinol on maintaining healthy cardiovascular health in overweight and obese adults. Subjects took 3 capsules, 3 times per day over a period of 12 weeks.

Conditions

Interventions

DIETARY_SUPPLEMENT

Neoprinol

Sponsors & Collaborators

  • Arthur Andrew Medical

    collaborator UNKNOWN

  • KGK Science Inc.

    lead INDUSTRY

Principal Investigators

  • Aaron Gillam · Arthur Andrew Medical

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2014-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02862223 on ClinicalTrials.gov